Merck Posts Q2 EPS Beat Revenue Slips
(NYSE:MRK), a leading developer of prescription medicines, vaccines, and animal health products, released its second-quarter 2025 results on July 29, 2025. The most notable news was a beat on earnings per share, with non-GAAP EPS at $2.13 versus estimates of $2.02, a 5 % outperformance, even as GAAP revenue of $15.8 billion fell 0.58% short of consensus expectations. The quarter saw continued sales strength from its blockbuster oncology drug KEYTRUDA, which generated $8.0 billion in sales, but a steep drop in GARDASIL vaccine sales due to demand declines in China. Overall, the period highlighted both the resilience of Merck’s core oncology franchise and ongoing challenges in selected vaccine and international markets.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
(NYSE:MRK) is a global pharmaceutical company specializing in innovative prescription medicines, vaccines, and animal health products. Its top-selling therapy is KEYTRUDA, an immuno-oncology drug that targets advanced and early-stage cancers across many indications. The company’s broader portfolio also includes important vaccines like GARDASIL (human papillomavirus vaccine), diabetes drugs, hospital acute care medicines, and a robust animal health division.
Source Fool.com
Merck KGaA Stock
Merck KGaA is currently one of the favorites of our community with 8 Buy predictions and no Sell predictions.
As a result the target price of 157 € shows a positive potential of 43.64% compared to the current price of 109.3 € for Merck KGaA.
